» Articles » PMID: 29875250

CD8 T Cell Responses to an Immunodominant Epitope Within the Nonstructural Protein NS1 Provide Wide Immunoprotection Against Bluetongue Virus in IFNAR Mice

Overview
Journal J Virol
Date 2018 Jun 8
PMID 29875250
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The development of vaccines against bluetongue, a prevalent livestock disease, has been focused on surface antigens that induce strong neutralizing antibody responses. Because of their antigenic variability, these vaccines are usually serotype restricted. We now show that a single highly conserved nonstructural protein, NS1, expressed in a modified vaccinia Ankara virus (MVA) vector can provide multiserotype protection in IFNAR 129 mice against bluetongue virus (BTV) that is largely dependent on CD8 T cell responses. We found that the protective antigenic capacity of NS1 resides within the N terminus of the protein and is provided in the absence of neutralizing antibodies. The protective CD8 T cell response requires the presence of a specific peptide within the N terminus of NS1, since its deletion ablates the efficacy of the vaccine formulation. These data reveal the importance of the nonstructural protein NS1 in CD8 T cell-mediated protection against multiple BTV serotypes when vectorized as a recombinant MVA vaccine. Conventional vaccines have controlled or limited BTV expansion in the past, but they cannot address the need for cross-protection among serotypes and do not allow distinguishing between infected and vaccinated animals (DIVA strategy). There is a need to develop universal vaccines that induce effective protection against multiple BTV serotypes. In this work we have shown the importance of the nonstructural protein NS1, conserved among all the BTV serotypes, in CD8 T cell-mediated protection against multiple BTV serotypes when vectorized as a recombinant MVA vaccine.

Citing Articles

Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.

Jimenez-Cabello L, Utrilla-Trigo S, Calvo-Pinilla E, Lorenzo G, Illescas-Amo M, Benavides J Front Immunol. 2024; 15:1440407.

PMID: 39072326 PMC: 11272488. DOI: 10.3389/fimmu.2024.1440407.


Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of Bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccine.

Kolla H, Dutt M, Kumar A, Hebbandi Nanjunadappa R, Karakach T, Singh K Front Immunol. 2024; 15:1424307.

PMID: 39011043 PMC: 11246920. DOI: 10.3389/fimmu.2024.1424307.


Specific T-cell subsets have a role in anti-viral immunity and pathogenesis but not viral dynamics or onwards vector transmission of an important livestock arbovirus.

Newbrook K, Khan N, Fisher A, Chong K, Gubbins S, Davies W Front Immunol. 2024; 15:1328820.

PMID: 38357545 PMC: 10864546. DOI: 10.3389/fimmu.2024.1328820.


Engineering recombinant replication-competent bluetongue viruses expressing reporter genes for and non-invasive studies.

Utrilla-Trigo S, Jimenez-Cabello L, Marin-Lopez A, Illescas-Amo M, Andres G, Calvo-Pinilla E Microbiol Spectr. 2024; 12(3):e0249323.

PMID: 38353566 PMC: 10923215. DOI: 10.1128/spectrum.02493-23.


Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.

Jimenez-Cabello L, Utrilla-Trigo S, Barreiro-Pineiro N, Pose-Boirazian T, Martinez-Costas J, Marin-Lopez A Vaccines (Basel). 2022; 10(7).

PMID: 35891288 PMC: 9319458. DOI: 10.3390/vaccines10071124.


References
1.
Calvo-Pinilla E, Rodriguez-Calvo T, Sevilla N, Ortego J . Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine. 2009; 28(2):437-45. DOI: 10.1016/j.vaccine.2009.10.027. View

2.
Parker J, HERNIMAN K, Gibbs E, Sellers R . An experimental inactivated vaccine against bluetongue. Vet Rec. 1975; 96(13):284-7. DOI: 10.1136/vr.96.13.284. View

3.
Matsuo E, Roy P . Minimum requirements for bluetongue virus primary replication in vivo. J Virol. 2012; 87(2):882-9. PMC: 3554043. DOI: 10.1128/JVI.02363-12. View

4.
Chen T, Li D, Song Y, Yang X, Liu Q, Jin X . A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice. Antiviral Res. 2017; 145:54-59. DOI: 10.1016/j.antiviral.2017.07.009. View

5.
Huismans H, van der Walt N, Cloete M, Erasmus B . Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep. Virology. 1987; 157(1):172-9. DOI: 10.1016/0042-6822(87)90326-6. View